Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLCПодробнее

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC

MARIPOSA: longer-term follow-up of amivantamab & lazertinib in EGFR-m NSCLCПодробнее

MARIPOSA: longer-term follow-up of amivantamab & lazertinib in EGFR-m NSCLC

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib

Dr. Gadgeel Discusses Updated MARIPOSA Results at IASLC 2024 World Conference on Lung CancerПодробнее

Dr. Gadgeel Discusses Updated MARIPOSA Results at IASLC 2024 World Conference on Lung Cancer

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLCПодробнее

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

EGFR TKI Resistance: Progress and ChallengesПодробнее

EGFR TKI Resistance: Progress and Challenges

Amivantamab Plus Lazertinib for EGFR-Mutant Lung Cancer Following Progression on OsimertinibПодробнее

Amivantamab Plus Lazertinib for EGFR-Mutant Lung Cancer Following Progression on Osimertinib

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLCПодробнее

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC